Snipr Biome to send first candidate to clinic

The FDA has given Danish CRISPR company Snipr Biome the thumbs-up to begin clinical testing of its drug candidate that targets E. coli infections. A phase I trial is scheduled to begin in the first half of 2022.

Christian Grøndahl, co-founder and CEO of Snipr, can look forward to an exciting year ahead, as the company can begin clinically testing its first development candidate | Photo: EY / PR

CRISPR company Snipr Biome has an exciting year ahead, as the US Food and Drug Administration (FDA) has approved the company's application to initiate a phase I clinical trial with the company's first development candidate, SNIPR001, which is designed to target E. coli in the gut, a press release announces.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs